secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001477932-24-001328
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer effective April 1, 2024
--------------------------------------------------------------------------------

- Dr. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust, London, and dual-registered in Intensive Care and Haematology.
- He has advised Volition since January 2022 on Nu.Q® NETs, a CE-marked blood test for sepsis and NETosis-related diseases.
- As CMO, he will lead medical strategy and ensure clinical efforts are aligned with patient needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224001328/0001477932-24-001328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224001328/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-001328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer